Sanofi has successfully priced an offering of 2 billion euros ($2.26 billion) of notes, a move which the company says is aimed at lowering its average cost of debt and extending the average maturity of its debt.
Sanofi says it plans to use the net proceeds of the offering for “general corporate purposes.”
BofA - Merrill Lynch and Natixis acted as global coordinators and bookrunners, with ING and Santander acting as bookrunners for the offering.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze